The identification of PRC2-regulated metastatic pathways identified in this study provides strong preclinical rationale for developing therapies targeting ECM-remodeling enzymes and tumor fibrosis to improve outcomes in patients with MPNST. The gene discussed is MMRN1; the disease is neoplasm.